GO
Loading...

Gilead Sciences Inc

More

  • Gilead says 1Q sales of Sovaldi totaled $2.27B Tuesday, 22 Apr 2014 | 5:41 PM ET

    NEW YORK— Gilead Sciences said Tuesday that sales of its hepatitis C pill Sovaldi totaled more than $2 billion in its first full quarter on the market, and it said quarterly net income tripled. The company reported $2.27 billion in first-quarter sales of Sovaldi, which was launched in the U.S. during December and was approved in Europe in January.

  • April 22- Gilead Sciences Inc, which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.

  • April 22- Gilead Sciences Inc, whose pricing policy ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.

  • Final Glance: Biotechnology companies Monday, 21 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose $1.56 or 1.4 percent, to $117.02. Biogen Idec rose $7.44 or 2.6 percent, to $297.98. Celgene Corp. rose $2.32 or 1.6 percent, to $143.83.

  • Midday Glance: Biotechnology companies Monday, 21 Apr 2014 | 1:20 PM ET

    Amgen Inc. rose$. 89 or. 8 percent, to $116.35. Biogen Idec rose $3.44 or 1.2 percent, to $293.98. Celgene Corp. rose $1.03 or. 7 percent, to $142.54.

  • Most active Nasdaq-traded stocks Monday, 21 Apr 2014 | 1:20 PM ET

    Cisco Systems Inc. rose. 8 percent to $23.40 with 38,516,700 shares traded. Facebook Inc. rose 3.9 percent to $61.24 with 58,657,400 shares traded. FuelCell Energy Inc. rose 2.9 percent to $2.52 with 17,673,900 shares traded.

  • Can Gilead’s Sovaldi rescue biotech? Monday, 21 Apr 2014 | 12:20 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.

  • Early Glance: Biotechnology companies Monday, 21 Apr 2014 | 10:31 AM ET

    Amgen Inc. rose$. 91 or. 8 percent, to $116.37. Biogen Idec rose $3.58 or 1.2 percent, to $294.12. Celgene Corp. rose $1.63 or 1.2 percent, to $143.14.

  • Here's what will drive stocks this week Sunday, 20 Apr 2014 | 4:46 PM ET

    About 150 S&P 500 companies are scheduled to release results this week, in an earnings season that has been mediocre.

  • April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.

  • Doctors urged to weigh costs in treatment decisions Friday, 18 Apr 2014 | 12:00 AM ET

    Some medical groups now want doctors to consider both the effectiveness and costs of treatment options.

  • Several behemoths, including Apple, the largest U.S. company by market value, as well as Microsoft, McDonald's and AT&T, are due to report earnings.

  • *Google, IBM shares fall a day after posting earnings. NEW YORK, April 17- U.S. stocks ended a holiday-shortened week with mostly modest gains on Thursday, though the S&P 500 notched its biggest weekly advance since July as Morgan Stanley and General Electric rallied after strong results.

  • US STOCKS-Wall St edges higher during earnings flurry Thursday, 17 Apr 2014 | 1:40 PM ET

    *Google, IBM shares fall a day after posting earnings. NEW YORK, April 17- U.S. stocks advanced slightly in choppy trading on Thursday after three days of gains, as underwhelming results from tech bellwethers Google and IBM were offset by upbeat quarterly numbers, including those from Morgan Stanley and General Electric.

  • Midday movers: Weibo, Sabre, Goldman Sachs & More Thursday, 17 Apr 2014 | 12:30 PM ET
    Sign for Sabre IPO on Nasdaq board

    Some of Thursday's midday movers:

  • April 17- UnitedHealth Group Inc, the largest U.S. health insurer, said on Thursday it has spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc, a higher cost than it expected by "multiples," sending shares in the sector lower.

  • The $9.4 billion Fidelity Select Biotechnology Fund plunged 11.75 percent during the first 14 days of April. That put the fund near the bottom among nearly 3,800 U.S. mutual funds tracked by Lipper Inc. Only six funds performed worse, but they had less than $100 million in assets each.

  • UnitedHealth's 1Q profit tumbles 8 percent Thursday, 17 Apr 2014 | 6:27 AM ET

    UnitedHealth Group's first-quarter net income slid 8 percent as funding cuts to a key product and costs imposed by the health care overhaul dented the health insurer's performance.

  • Final Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose$. 54 or. 5 percent, to $115.54. Biogen Idec rose $5.99 or 2.1 percent, to $291.48. Celgene Corp. rose $2.02 or 1.4 percent, to $141.86.

  • Midday Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 1:30 PM ET

    Amgen Inc. rose$. 17 or. 1 percent, to $115.17. Biogen Idec rose $5.59 or 2.0 percent, to $291.08. Celgene Corp. rose $1.52 or 1.1 percent, to $141.36.

Most Popular Video

Tuesday, 22 Apr 2014 | 10:48 PM ET

Todd Elmer, Currency Strategist at Citi, discusses whether the currency's sharp drop following weaker-than-expected quarterly inflation data was justified.

Tuesday, 22 Apr 2014 | 10:30 PM ET

Adaire Fox-Martin, COO, Asia Pacific Japan at SAP, elaborates on the firm's "stunning results" in Southeast Asia, India and the sector of cloud computing in the first-quarter.

Tuesday, 22 Apr 2014 | 10:17 PM ET

Joe Magyer, Senior Analyst at The Motley Fool, says the flurry of activity on Wall Street looks "frothy" at the moment.